TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of “Moderate Buy” by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $152.3333.

A number of research firms recently weighed in on TMDX. Canaccord Genuity Group upped their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Needham & Company LLC upped their target price on shares of TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. JPMorgan Chase & Co. upped their target price on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Stifel Nicolaus upped their target price on shares of TransMedics Group from $115.00 to $130.00 and gave the company a “hold” rating in a research note on Monday, March 9th. Finally, TD Cowen reissued a “buy” rating on shares of TransMedics Group in a research note on Monday, March 16th.

Insider Activity

In other TransMedics Group news, Director David Weill sold 3,571 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $146.82, for a total transaction of $524,294.22. Following the sale, the director directly owned 12,134 shares of the company’s stock, valued at approximately $1,781,513.88. This represents a 22.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anil P. Ranganath sold 864 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $120,199.68. Following the sale, the insider directly owned 13,091 shares in the company, valued at $1,821,219.92. This represents a 6.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 16,205 shares of company stock valued at $2,353,002. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Several large investors have recently added to or reduced their stakes in TMDX. Royal Bank of Canada grew its stake in TransMedics Group by 47.9% during the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after buying an additional 8,604 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in TransMedics Group by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after buying an additional 868 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares during the last quarter. Russell Investments Group Ltd. grew its stake in TransMedics Group by 13.5% during the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock worth $1,059,000 after buying an additional 938 shares during the last quarter. Finally, M&T Bank Corp bought a new stake in TransMedics Group during the second quarter worth about $209,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $114.00 on Monday. The stock has a market cap of $3.91 billion, a P/E ratio of 23.27 and a beta of 2.09. The company’s 50-day simple moving average is $123.84 and its 200 day simple moving average is $126.44. TransMedics Group has a twelve month low of $75.50 and a twelve month high of $156.00. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.